

# PROVIDER BULLETIN

## PROVIDER INFORMATION



December 5, 2016

### **Update on New Drug, Ocrevus™ (ocrelizumab)**

*The information in this Bulletin replaces the Provider Bulletin entitled “A New Drug, Ocrevus to require Prior Authorization” that was published on September 9, 2016.*

As previously communicated via the September 9, 2016 bulletin referenced above, Ocrevus™ (ocrelizumab) is a new drug anticipated to be approved for Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Remitting Multiple Sclerosis (RRMS), and is expected to be approved on or after December 26, 2016.

Due to Ocrevus' intravenous route of administration, Ocrevus will be excluded from pharmacy benefit coverage. Ocrevus will be available for medical benefit coverage for subscribers who are eligible. There is currently no Prior Authorization (PA) requirement for Ocrevus under the medical benefit.

### **Products Impacted**

This notice applies to commercial lines of business **and** the following Minnesota Health Care Programs:

- Blue Advantage Prepaid Medical Assistance Program (PMAP)
- Minnesota Senior Care Plus (MSC+)
- MinnesotaCare

### **Questions?**

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.